Reuters logo
BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products
2017年8月31日 / 晚上9点35分 / 22 天前

BRIEF-Aptevo Therapeutics signs agreement for up to $74.5 mln to sell Hyperimmune Commercial Products

Aug 31 (Reuters) - Aptevo Therapeutics Inc:

* Aptevo Therapeutics signs agreement for up to $74.5 million to sell hyperimmune commercial products

* Aptevo - deal valued at up to $74.5 million, including an upfront payment of $65 million, and an additional potential milestone payment of up to $7.5 million​

* Aptevo Therapeutics Inc - co may receive up to $2 million related to collection of certain accounts receivable after closing of deal

* Aptevo Therapeutics Inc - ‍agreed to sell its three marketed hyperimmune products, winrho sdf, hepagam b, and varizig, to saol therapeutics​

* Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to satisfy current debt obligation to midcap financial​

* Aptevo Therapeutics - ‍anticipates that proceeds from sale of hyperimmune products will be used to advance clinical and preclinical adaptir candidates​ Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below